The Overlooked Aspect of GLP-1 Receptor Agonists: Psychiatric and Behavioral Effects
Keywords:
GLP-1 receptor agonists, semaglutide, tirzepatide, psychiatric adverse events, mental health, pharmacovigilanceAbstract
Letter to the Editor: Glucagon-like peptide-1 (GLP-1) receptor agonists—including semaglutide, liraglutide, and dual GIP/GLP-1 receptor agonists such as tirzepatide—have revolutionized the pharmacological management of type 2 diabetes mellitus and obesity, with expanding evidence for cardiovascular and renal protection. However, as clinical utilization rapidly broadens across diverse patient populations, emerging pharmacovigilance signals and clinical reports have drawn attention to potential neuropsychiatric and behavioral effects, including mood alterations, anxiety, anhedonia, reward-pathway modulation, and rare reports of suicidal ideation. Because GLP-1 receptors are expressed in central nervous system regions governing appetite, reward processing, and emotional regulation (such as the hypothalamus, ventral tegmental area, and nucleus accumbens), clinicians across primary care, endocrinology, and psychiatry should integrate baseline mental health screening and ongoing psychiatric monitoring into routine follow-up for patients receiving GLP-1 receptor agonist therapy.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
European Medicines Agency (EMA). PRAC concludes that available evidence does not support link between GLP-1 receptor agonists and suicidal and self-injurious thoughts and actions. EMA Pharmacovigilance Risk Assessment Committee Report; 2024.
McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: What do we know and what do clinicians need to know? Am J Psychiatry. 2024;181(5):372-375.
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort study. Nat Med. 2024;30(1):168-176.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ayşegül Çoban

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.